139 related articles for article (PubMed ID: 15453331)
1. [Introduction to chronic hepatitis type B].
Inoue O; Nakagawa Y; Mawatari H
Nihon Rinsho; 2004 Aug; 62 Suppl 8():285-9. PubMed ID: 15453331
[No Abstract] [Full Text] [Related]
2. [Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].
Ishikawa T; Kakumu S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():331-5. PubMed ID: 15453340
[No Abstract] [Full Text] [Related]
3. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Sponseller CA; Bacon BR; Di Bisceglie AM
Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
[TBL] [Abstract][Full Text] [Related]
4. Designing clinical development programs for anti-hepatitis B virus drugs.
Brown NA
Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
[No Abstract] [Full Text] [Related]
5. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of hepatitis B].
Telegdy L
Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia.
Lazarevic I; Cupic M; Delic D; Svirtlih NS; Simonovic J; Jovanovic T
J Med Virol; 2010 Jul; 82(7):1160-7. PubMed ID: 20513079
[TBL] [Abstract][Full Text] [Related]
8. [Lamivudine treatment of patients with decompensated HBV cirrhosis and mutation in YMDD motif].
Wei L
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):77-8. PubMed ID: 15670511
[No Abstract] [Full Text] [Related]
9. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
[TBL] [Abstract][Full Text] [Related]
10. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
11. [Chronic hepatitis B].
Thimme R; Spangenberg HC; Blum HE
Dtsch Med Wochenschr; 2008 Jan; 133(4):135-8. PubMed ID: 18197589
[No Abstract] [Full Text] [Related]
12. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
13. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy.
Zhang JM; Wang XY; Huang YX; Yin YK; Guan S; Xu Y; Roggendorf M; Lu M
J Med Virol; 2006 Mar; 78(3):324-8. PubMed ID: 16419112
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
Yuan J; Zhou BP; Gong ZJ; Xu LM; Jiang XL; Mizokami M
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
[TBL] [Abstract][Full Text] [Related]
15. [Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B].
Yan MH; Zhang C; Ling Q; Zhou RF
Zhonghua Gan Zang Bing Za Zhi; 2003 Jul; 11(7):430-1. PubMed ID: 12890351
[No Abstract] [Full Text] [Related]
16. Natural history of chronic hepatitis B.
McMahon BJ
Clin Liver Dis; 2010 Aug; 14(3):381-96. PubMed ID: 20638020
[TBL] [Abstract][Full Text] [Related]
17. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
Tsubota A
J Gastroenterol Hepatol; 2006 Dec; 21(12):1769-71. PubMed ID: 17074012
[No Abstract] [Full Text] [Related]
18. Liver disease-significant improvement with lamivudine.
Leung N
J Med Virol; 2000 Jul; 61(3):380-5. PubMed ID: 10861650
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and problems in combination therapy using lamivudine and interferon for chronic hepatitis B].
Saito T; Watanabe H; Togashi H; Kawata S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():326-30. PubMed ID: 15453339
[No Abstract] [Full Text] [Related]
20. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
